Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer
Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer
复制标题
DOI：
10.1097/01.ju.0000125123.46733.93
复制
发表时间：
2004-06-01
影响因子：
6.6
通讯作者：
Resnick, MI
中科院分区：
文献类型：
--
作者：
Oefelein, MG;Resnick, MI
目的：我们确定的时间激素难治性前列腺癌（HRPC）的发展和生存的男性晚期前列腺癌，并检查任何与吸烟history.Materials和方法：研究设计是回顾性的。在222例晚期前列腺癌患者中获得了完整的烟草史。在这222例患者中，133例诊断为HRPC，77例死亡。标准的统计方法和软件被用来分析这些data.Results：中位时间HRPC为11，23和35个月的患者与当前，以前或从未吸烟史（P = 0.00001）。中位总生存时间为38，47和60个月的雄激素消融治疗的患者，目前，以前或从未吸烟史，分别（p = 0.00001）。结论：烟草使用独立相关的时间HRPC和生存的剂量依赖性方式在晚期前列腺癌患者雄激素剥夺治疗。
Purpose: We identified time to the development of hormone refractory prostate cancer (HRPC) and survival in men with advanced prostate cancer and examined any association with cigarette smoking history.Materials and Methods: The study design was retrospective. A complete tobacco history was obtained in 222 patients with advanced prostate cancer. HRPC was diagnosed in 133 of these 222 patients and death occurred in 77. Standard statistical methods and software were used to analyze these data.Results: Median time to HRPC was 11, 23 and 35 months in patients with a current, former or never smoked tobacco history (p = 0.00001). Median overall survival time on androgen ablative therapy was 38, 47 and 60 months in patients with a current, former or never smoked tobacco history, respectively (p = 0.00001).Conclusions: Tobacco use independently correlates with time to HRPC and survival in a dose dependent manner in patients with advanced prostate cancer on androgen deprivation therapy.